OpenAI researcher Miles Wang is planning on leaving the firm to launch a new AI drug discovery startup, TechCrunch reported citing sources. Wang is in talks to raise about $200 million at a $2 billion valuation, with Lightspeed leading the round, the report added. The startup will reportedly work on AI models to help find new uses for existing drugs.